Autoimmunity

Innovent Announces Retirement of CFO and Appointment of New CFO

Retrieved on: 
Monday, February 5, 2024

Mr. Ede joined Innovent in 2017 and, during his CFO tenure, has made significant contributions to the Company's strategy planning, corporate governance, financial management and business development.

Key Points: 
  • Mr. Ede joined Innovent in 2017 and, during his CFO tenure, has made significant contributions to the Company's strategy planning, corporate governance, financial management and business development.
  • At the same time, Innovent has appointed Ms. Fei You as the new CFO, effective February 5, 2024.
  • "We are deeply grateful for the dedication and contribution Ronnie has made during his entire tenure at Innovent.
  • "At the same time, we warmly welcome Ms. Fei You as our new CFO.

NexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Friday, February 2, 2024

The closing of the offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about February 6, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to the Company from the offering are expected to be approximately $3.67 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.
  • The offering of the shares of common stock (or common stock equivalents) to be issued in the registered direct offering are being made only by means of a prospectus supplement that forms a part of the registration statement.
  • A final prospectus supplement and an accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Retrieved on: 
Thursday, February 1, 2024

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.

Key Points: 
  • PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Tuesday, February 8th, 2024 at 2:30 PM ET.
  • A replay of the event will be available on the “Events & Presentations” page in the “Investors” section of the Company’s website at https://investors.centurytx.com/events-and-presentations and will be available for 90 days following the event.

Meso Numismatics Increases 2023 Sales By 50% Year Over Year and Announces 2024 Forecast and Outlook

Retrieved on: 
Wednesday, January 31, 2024

Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures.

Key Points: 
  • Sales were derived from its 4 main channels, Training, Product sales, Equipment sales and Patient procedures.
  • The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February.
  • The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location.
  • "We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business.

Revolo Biotherapeutics Receives Orphan Drug Designation from the U.S. FDA for its First-in-Class Peptide as a Potential Treatment for Eosinophilic Esophagitis

Retrieved on: 
Tuesday, January 30, 2024

Revolo submitted its original request prior to the initiation of its Phase 2a EoE study (RVLO 121-04) and submitted an amended request following positive results from an additional Phase 2 study.

Key Points: 
  • Revolo submitted its original request prior to the initiation of its Phase 2a EoE study (RVLO 121-04) and submitted an amended request following positive results from an additional Phase 2 study.
  • A statistically significant reduction in eosinophils, CD4+, and CD8+ cells from baseline as measured in esophageal tissue by flow cytometry.
  • A statistically significant increase in T regulatory cells in esophageal tissue and B regulatory cells in the blood, respectively.
  • The trial will evaluate higher dose levels of ‘1104 and a longer duration of therapy.

Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences

Retrieved on: 
Thursday, February 1, 2024

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences.
  • Thursday, February 8th, the Company will participate in a fireside chat at 10:00 am ET/7:00 am PT during the Guggenheim 6th Annual Biotechnology Conference in New York, NY and host investor meetings the same day.
  • Wednesday, February 14th, the Company will participate in a fireside chat during the virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference at 12:00 pm ET/9:00 am PT and host investor meetings the same day.
  • Live webcasts of the fireside chats will be available in the investor relations section of the Company’s website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days following the event.

Infinity Bio Launches Next-Generation Antibody Profiling Platform Utilizing MIPSA Technology

Retrieved on: 
Wednesday, January 31, 2024

Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.

Key Points: 
  • Infinity Bio , Inc. announces its new antibody profiling platform, leveraging Molecular Indexing of Proteins by Self-Assembly ( MIPSA ) technology.
  • Infinity Bio's proprietary MIPSA technology is a leap forward in antibody profiling.
  • This capability places Infinity Bio at the forefront of disease research, biomarker discovery, monoclonal antibody optimization, vaccine development, and therapeutic advancement.
  • H. Benjamin Larman, Ph.D., co-founder and CSO of Infinity Bio and Associate Professor of Pathology at Johns Hopkins School of Medicine, explains, “Infinity Bio was formed to elucidate each individual’s portfolio of antibodies.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

Retrieved on: 
Wednesday, January 31, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
    In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
  • Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
  • This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
  • “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications

Retrieved on: 
Tuesday, January 30, 2024

The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.

Key Points: 
  • The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.
  • This anticipated surge in demand for advanced neurological diagnostics and monitoring solutions underscores the significance of Aditxt's strategic acquisition of these assets.
  • Neurological monitoring solutions that enable real-time, continuous brain activity tracking prove invaluable in critical care settings where timely information can be lifesaving.
  • Ernie Lee, CEO of Pearsanta, remarked, "We recognize the immense potential within neuro deficit disorders, diagnosis, and monitoring.

2seventy bio Announces New Strategic Path Forward

Retrieved on: 
Tuesday, January 30, 2024

2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.

Key Points: 
  • 2seventy bio, in partnership with Bristol Myers Squibb (BMS), is taking actions to return Abecma to commercial growth in 2024.
  • 2seventy bio and BMS are expanding its Abecma site footprint to enable more patients to access the treatment.
  • Upon closing of the transaction with Regeneron, Chip Baird, chief operating officer, will become chief executive officer of 2seventy bio.
  • After 13 years of service on the bluebird bio and 2seventy bio Board of Directors, Dan Lynch will step down from the Board in June and will continue in an advisory role for 2seventy bio.